The Health 202: Years after an experimental stem cell therapy blinded patients, the FDA is still trying to stop it
Apr 04, 2019 - Washington Post Blogs
Board and Executive Moves
THE PROGNOSIS
The Food and Drug Administration promised yesterday to heighten oversight of providers of experimental stem cell treatments, as a Post report detailed the agency's slow response to a leading stem cell company whose treatments blinded some patients.
U.S. Stem Cell had $6.7 million in revenue last year, operates three clinics and has trained doctors at 150 others, making it a leading stem cell treatment provider in the burgeon...
Sign up today to gain access to 5 free articles a month from over 200 top subscription outlets.
Are you ready to take your business development to the next level with RelSci Professional?
Nurture your network with daily alerts that notify you when your relationships make news
Map your relationships to any target or prospect to identify a warm introduction
Access unlimited deep dossiers on over 8 million decision makers
Best of all, you can try out all these powerful business development tools absolutely free for 30 days!
Check out News Home to stay on top of the people and organizations you care most about.
